October,24,2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") that it has reached preliminary cooperation intentions with clients at the "Medlab Asia & Asia Health 2022" event in Bangkok. At the event site, BioSpring's business team communicated and communicated with customers from Nepal, Bhutan, and Timor-Leste, and the two parties reached preliminary intentions on business cooperation and product registration submissions. The client…
August 18, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Phase 1 of the manufacturing unit was constructed and delivered. This time, the delivery of the manufacturing unit constructed according to the ICH1-GMP2 standard is the first step for BioSpring to serve global users. With the strong support and joint efforts of the Vientiane government of Laos and the Saysettha Comprehensive Development Zone,…
BioSpring will acquire all formulations, processes and equipment for SAILIN's anticancer drug product line. BioSpring's acquisition of SAILIN includes its brand, but BioSpring does not operate its brand. All acquisitions are expected to be completed by the end of this year. July 27, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Acquisition of Laos Anticancer Drug Company Sailin biopharma. The acquisition…
BioSpring is the first third-party formula manufacturing pharmaceutical company in Laos to expand the global market Long-term development goals include serving Southeast Asia, South Asia, Arabia, Eastern Europe, Central Asia, West Asia, Africa, Latin America and other markets Planned product lines include epidemiological drugs, oncology drugs, rare disease drugs, and long-term care and companion animal drugs June 14, 2022, Vientiane, Laos–BioSpring…
